Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Advanced Solid Tumors 1Adenocarcinoma of the Stomach 1

Interventions

Docetaxel 21Radiosurgery 20Radiotherapy 17Androgen Antagonists 14Leuprolide 12Goserelin 12bicalutamide 11Prednisone 9Gonadotropin-Releasing Hormone 9Abiraterone Acetate 9enzalutamide 8Surveys and Questionnaires 8Radiotherapy, Intensity-Modulated 8Brachytherapy 8Blood Specimen Collection 8acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7Triptorelin Pamoate 7Multiparametric Magnetic Resonance Imaging 7abiraterone 5pembrolizumab 4cabazitaxel 4Standard of Care 4Positron Emission Tomography Computed Tomography 4Metformin 4Heavy Ion Radiotherapy 4Flutamide 4Exercise 4Estramustine 4luprolide acetate gel depot 3darolutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Prostatic Neoplasms × tesetaxel × Clear all
NCT01296243 2012-07-24

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Genta Incorporated

Phase 2 Unknown
57 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡